Trading Report: The Bluebird Bio Inc. (BLUE) PT Raised to $80.00 at Leerink Swann

The Bluebird Bio Inc. (BLUE) PT Raised to $80.00 at Leerink Swann

Bluebird Bio Inc. (NASDAQ:BLUE) had its price objective hoisted by equities researchers at Leerink Swann from $67.00 to $80.00 in a research report issued on Friday. The brokerage currently has an “outperform” rating on the stock. Leerink Swann’s price target would indicate a potential upside of 22.62% from the stock’s current price.

BLUE has been the topic of a number of other reports. Jefferies Group restated a “buy” rating and set a $80.00 price target on shares of Bluebird Bio in a research report on Friday, September 23rd. Zacks Investment Research lowered shares of Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. SunTrust Banks Inc. restated a “buy” rating on shares of Bluebird Bio in a research report on Friday. Maxim Group set a $85.00 price target on shares of Bluebird Bio and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Finally, Cowen and Company restated an “outperform” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $90.82.

Bluebird Bio (NASDAQ:BLUE) traded down 5.9497% during mid-day trading on Friday, reaching $61.3584. 889,442 shares of the company were exchanged. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $99.70. The company’s market capitalization is $2.28 billion. The company has a 50 day moving average of $63.52 and a 200-day moving average of $50.81.

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The company earned $1.55 million during the quarter, compared to analyst estimates of $2.01 million. During the same quarter last year, the business earned ($1.57) EPS. The firm’s revenue for the quarter was down 68.6% compared to the same quarter last year. On average, equities research analysts forecast that Bluebird Bio will post ($6.19) EPS for the current year.

In related news, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the sale, the insider now directly owns 4,656 shares of the company’s stock, valued at approximately $209,706.24. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 3.50% of the company’s stock.

A number of large investors have recently made changes to their positions in the company. Cupps Capital Management LLC acquired a new stake in shares of Bluebird Bio during the third quarter valued at $1,824,000. Gradient Investments LLC acquired a new stake in shares of Bluebird Bio during the third quarter valued at $333,000. First Mercantile Trust Co. acquired a new stake in shares of Bluebird Bio during the third quarter valued at $129,000. BNP Paribas Arbitrage SA increased its stake in shares of Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock valued at $209,000 after buying an additional 1,619 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Bluebird Bio by 43.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 145,569 shares of the company’s stock valued at $6,302,000 after buying an additional 44,048 shares during the last quarter.

Bluebird Bio Company Profile

Related posts

Leave a Comment